NEW YORK (GenomeWeb) – Cantor Fitzgerald today initiated coverage of miRNA-based diagnostics firm Rosetta Genomics with a Hold rating and a $4 price target on the company's stock.

Analyst Sung Ji Nam said in a report that while Rosetta is a "pioneer" in the miRNA Dx space, a lack of clinical evidence that its products improve patient outcomes has held back the company. Rosetta currently offers four cancer diagnostic tests through its CLIA laboratory, including the Cancer Origin Test, which, Nam said, comprises the majority of Rosetta's revenues.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.